TCIS Africa 2026 Highlights Africa’s Rise as the Next Global Hub for Clinical Trials

Global partnerships and digital innovation are accelerating clinical research capacity across the continent For too ...
Nasdaq

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Exact presentation times may be subject to change. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience.
Nasdaq

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / ...

Belay Diagnostics Reports 82% Clinical Impact Rate for Summit(TM) and Vantage(TM) in CNS Lymphoma Study

Belay Diagnostics announced the publication of a new retrospective study demonstrating that its Summit and Vantage tests provided meaningful clinical impact in 82% of CNS lymphoma cases evaluated. The ...
WCBD

SUMMIT CLINICAL RESEARCH ACQUIRES HOUSTON RESEARCH INSTITUTE AND DEEPENS LEADERSHIP TEAM TO ACCELERATE GROWTH AND ENHANCE SCIENTIFIC EXPERTISE

NEW ORLEANS, May 1, 2025 /PRNewswire/ -- LongueVue Capital ("LVC") is pleased to announce that its portfolio company, Summit Clinical Research ("Summit" or the "Company"), in partnership with Pinnacle ...

What makes Summit Therapeutics (SMMT) one of the best large caps under $30

Summit Therapeutics (NASDAQ:SMMT) is one of the 15 large cap stocks under $30 with huge upside potential. On March 16, Jefferies downgraded its rating for Summit Therapeutics Inc. (NASDAQ:SMMT) from ...
Seeking Alpha

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

REDWOOD CITY, Calif. & MIAMI--(BUSINESS WIRE)-- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and ...